Literature DB >> 26602064

Nature and frequency of drug therapy alerts generated by clinical decision support in community pharmacy.

Mette Heringa1,2,3, Annemieke Floor-Schreudering1,2, P Chris Tromp3, Peter A G M de Smet4, Marcel L Bouvy1,2.   

Abstract

PURPOSE: The purpose of this study is to investigate the nature, frequency, and determinants of drug therapy alerts generated by a clinical decision support system (CDSS) in community pharmacy in order to propose CDSS improvement strategies.
METHODS: This is a retrospective analysis of dispensed drugs and drug therapy alerts generated by a CDSS in community pharmacies.
RESULTS: Data were extracted from the CDSS of 123 community pharmacies. After taking a 10% random sample of patients with a prescription in the period August 2013-July 2014, 1,672,169 dispensed prescriptions from 81,742 patients were included in the analysis. Of all processed prescriptions, 43% led to one or more drug safety alerts, most frequently drug-drug interaction alerts (15% of all prescriptions), drug-disease interaction alerts (14%), duplicate medication alerts (13%), and dosing alerts (7%). The majority of prescriptions with alerts (80%) were clustered in a minority of patients (16%). The therapeutic drug group of the prescribed drug was the most important determinant of alert generation. Prescriptions for antithrombotic agents accounted for 9.4% of all prescriptions with an alert, beta-blocking agents for 7.5% and angiotensin-converting-enzyme inhibitors for 6.1%. DISCUSSION AND
CONCLUSION: The investigated CDSS in Dutch community pharmacy generated one or more drug therapy alerts in nearly half of the processed prescriptions. The majority of alerts were concentrated in a minority of therapeutic drug groups and patients. To decrease the alert burden, CDSS improvements should be directed at the prioritization and integration of drug therapy alerts for these therapeutic groups within patients.
Copyright © 2015 John Wiley & Sons, Ltd.

Entities:  

Keywords:  clinical decision support systems; clinical risk management; community pharmacy; drug therapy alerts; pharmacoepidemiology; pharmacy information systems

Mesh:

Year:  2015        PMID: 26602064     DOI: 10.1002/pds.3915

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  9 in total

1.  Integrating Medication Alert Data into a Clinical Data Repository to Enable Retrospective Study of Drug Interaction Alerts in Clinical Practice.

Authors:  Mei Liu; Brittany L Melton; Gregory Ator; Lemuel R Waitman
Journal:  AMIA Jt Summits Transl Sci Proc       Date:  2017-07-26

2.  Potential Drug-Drug Interactions in a Cohort of Elderly, Polymedicated Primary Care Patients on Antithrombotic Treatment.

Authors:  Katharina Luise Schneider; Kathrin Kastenmüller; Klaus Weckbecker; Markus Bleckwenn; Miriam Böhme; Julia Carolin Stingl
Journal:  Drugs Aging       Date:  2018-06       Impact factor: 3.923

3.  The Development of Practice Recommendations for Drug-Disease Interactions by Literature Review and Expert Opinion.

Authors:  Justine M Z van Tongeren; S Froukje Harkes-Idzinga; Heleen van der Sijs; Roya Atiqi; Bart J F van den Bemt; L Willem Draijer; Deline Hiel; Adrian Kerremans; Bart Kremers; Marc de Leeuw; Marleen V Olthoff; T Kim-Loan Pham; Ricky Valentijn-Robertz; Kayan Tsoi; Iris Wichers; Maaike de Wit; Sander D Borgsteede
Journal:  Front Pharmacol       Date:  2020-05-15       Impact factor: 5.810

4.  Feasibility, acceptability and potential effectiveness of an information technology-based, pharmacist-led intervention to prevent an increase in anticholinergic and sedative load among older community-dwelling individuals.

Authors:  Helene G van der Meer; Hans Wouters; Martina Teichert; Fabiënne Griens; Jugoslav Pavlovic; Lisa G Pont; Katja Taxis
Journal:  Ther Adv Drug Saf       Date:  2018-10-30

5.  Effects of a clinical medication review focused on personal goals, quality of life, and health problems in older persons with polypharmacy: A randomised controlled trial (DREAMeR-study).

Authors:  Sanne Verdoorn; Henk-Frans Kwint; Jeanet W Blom; Jacobijn Gussekloo; Marcel L Bouvy
Journal:  PLoS Med       Date:  2019-05-08       Impact factor: 11.069

6.  Prevalence and Accuracy of Information on CYP2D6, CYP2C19, and CYP2C9 Related Substrate and Inhibitor Co-Prescriptions in the General Population: A Cross-Sectional Descriptive Study as Part of the PharmLines Initiative.

Authors:  Muh Akbar Bahar; Jens H J Bos; Sander D Borgsteede; Aafje Dotinga; Rolinde A Alingh; Bob Wilffert; Eelko Hak
Journal:  Front Pharmacol       Date:  2020-05-08       Impact factor: 5.810

7.  The use of a clinical decision support tool to assess the risk of QT drug-drug interactions in community pharmacies.

Authors:  Florine A Berger; Heleen van der Sijs; Teun van Gelder; Patricia M L A van den Bemt
Journal:  Ther Adv Drug Saf       Date:  2021-02-24

8.  Preferences of Patients and Pharmacists with Regard to the Management of Drug-Drug Interactions: A Choice-Based Conjoint Analysis.

Authors:  Mette Heringa; Annemieke Floor-Schreudering; Hans Wouters; Peter A G M De Smet; Marcel L Bouvy
Journal:  Drug Saf       Date:  2018-02       Impact factor: 5.606

9.  Nature and frequency of prescription modifications in community pharmacies: A nationwide study in the Netherlands.

Authors:  W E Ellen van Loon; S D Sander Borgsteede; G W Gert Baas; M Martine Kruijtbosch; H Henk Buurma; P A G M Peter De Smet; A C G Toine Egberts; M Marcel Bouvy; A Annemieke Floor-Schreudering
Journal:  Br J Clin Pharmacol       Date:  2020-09-24       Impact factor: 3.716

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.